top of page

Free Biopharma Daily Stock Updates - 09/30/21

$XBI $125.71 +0.06%

 

Covid Updates

$TRVN +0.8% Trevena Announces Results of TRV027 Proof-of-Concept Study in COVID-19 Patients source



Pipeline Updates

$DBTX -1.0% Decibel Therapeutics Announces Publication of Foundational Study of Noise-related Inner Ear Damage source


$IMNM +0.8% Immunome to Present Preclinical Data on Anti IL-38 Antibody Program at the American Association for Cancer Research NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics source


$INCY +0.1% OLUMIANT® Significantly Improved Hair Regrowth to At Least 80% Scalp Coverage as Early as 24 Weeks Across First Completed Phase 3 Studies for Alopecia Areata source


$ALZN +35.1% Alzamend Neuro Receives Positive Pre-IND Response from FDA for AL002, a Cell-Based Therapeutic Vaccine That Seeks to Restore the Ability of Patients’ Immunological System to Combat Alzheimer’s Disease source


$ADIL +2.6% ADIAL PHARMACEUTICALS ANNOUNCES GREATER THAN 50% OF PATIENTS EXPECTED TO COMPLETE ONWARD™ PHASE 3 TRIAL OF AD04 FOR THE TREATMENT OF ALCOHOL USE DISORDER HAVE COMPLETED THE FULL 24-WEEK TREATMENT PERIOD – TRIAL COMPLETION ANTICIPATED Q1 2022 source


$SMMT +3.7% Summit Therapeutics Presents Further Breakthrough Insights Surrounding the Novel Mechanism of Action for its Investigational Drug Ridinilazole During IDWeek 2021 source


$NERV -1.7% Minerva Neurosciences Announces Study Results Demonstrating Bioequivalence of Phase 2b, Phase 3, and Planned Commercial Formulations of Roluperidone for Treatment of Negative Symptoms of Schizophrenia source


$DMAC -0.7% DiaMedica Therapeutics Announces Fast Track Designation Granted to DM199 for the Treatment of Acute Ischemic Stroke source


$ARQT +5.7% New Data Highlighting Itch Reduction with Topical Roflumilast in Multiple Dermatologic Conditions Presented at European Academy of Dermatology and Venereology Congress source


$IMAB +1.8% I-Mab Reports Multiple Positive Clinical Updates of Differentiated CD47 Antibody Lemzoparlimab


$PSTV +0.5% PLUS THERAPEUTICS TO PRESENT RESPECT™-GBM CLINICAL TRIAL DATA AT THE 2021 SNO ANNUAL MEETING source


$ZGNX +0.7% New FINTEPLA® (Fenfluramine) Data Show Long-Term Seizure Frequency Reductions in Patients with Lennox-Gastaut Syndrome (LGS) source


$MRSN +1.0% Mersana Therapeutics to Announce Target and Present New Preclinical Data for XMT-2056 at the AACR-NCI-EORTC Virtual International Conference on Molecular Targets and Cancer Therapeutics source


$ARWR +3.0% Arrowhead Pharmaceuticals Initiates Phase 2b Study of ARO-APOC3 for Treatment of Mixed Dyslipidemia source


$PCRX -1.3% PACIRA ANNOUNCES COMMERCIAL PRODUCTION UNDERWAY WITH ENHANCED EXPAREL MANUFACTURING PROCESS AT SWINDON FACILITY source


$TGTX -0.9% TG Therapeutics Submits Biologics License Application to the U.S. Food and Drug Administration for Ublituximab as a Treatment for Patients with Relapsing Forms of Multiple Sclerosis source


$RVMD -0.6% Revolution Medicines to Present New Preclinical Data from RAS(ON) Inhibitor Programs at AACR-NCI-EORTC Virtual International Conference on Molecular Targets and Cancer Therapeutics source


$ADPT +4.7% Adaptive Biotechnologies Launches Enhanced clonoSEQ® Assay Reports for Patients with Chronic Lymphocytic Leukemia, Now Featuring IGHV Mutation Status source


$STRO +1.3% Sutro Biopharma Announces Extension of Cytokine Derivative Research Program Under Collaboration with Merck source


$RETA -4.5% Reata Pharmaceuticals Plans NDA Submission for Omaveloxolone in First Quarter of 2022 Following Completion of Pre-NDA Meeting with FDA source


$IMUX -2.6% Immunic, Inc. Enrolls First Patient in Its Phase 2 CALLIPER Trial of IMU-838 in Progressive Multiple Sclerosis source


Financial & Business Updates

$SPRO +1.3% Spero Therapeutics Enters Into a Non-Dilutive Revenue Interest Financing Agreement With HealthCare Royalty Partners® for Up to $125 Million source


$MRK +-0.0% MERCK TO ACQUIRE ACCELERON PHARMA INC. source


 

Posted by JM

0 comments
bottom of page